PLETHICO

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Plethico Pharmaceuticals Limited had informed the Exchange that the Company will publish the Quarterly / Yearly Audited Financial Results for the last quarter / year ending on December 31, 2010, within a period of 60 days from the end of Financial Year i.e. March 01, 2011. The Company has now informed the Exchange that since the audit of all the overseas subsidiaries are in process and the Company expect that Audit of the Annual Accounts of overseas subsidiaries for the Financial year ended on December 31, 2010 would be completed by March 25, 2011 the company will be able to publish consolidat

Plethico Pharmaceuticals Limited had submitted to the Exchange a copy of Corporate Presentation containing latest information regarding business overview, growth strategy, Key Financials etc. of the Company. The Company has now submitted to the Exchange a copy of Revised Corporate Presentation, after certain amendments/ updations made in the Presentation.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meetings held on February 14, 2011 considered the following: (1) Allotment of 20,00,000 warrants at a price of Rs.400/- per warrant, convertible into equity shares of Rs.10/- each fully paid up at a premium of Rs.390/- per share on a preferential allotment basis, to M/s Arum Investments Private Limited. (2) Approval of Statement of Advertisement under section 58A of the Companies Act, 1956 for acceptance of Deposits.

Plethico Pharmaceuticals Limited has informed the Exchange regarding "Medical Research Institute (MRI) Appoints Fitness Competitor/Trainer Kyle Clarke as an Athlete Spokesperson for the Brand".

Plethico Pharmaceuticals Limited has informed the Exchange that the Company will publish the Quarterly / Yearly Audited Financial Results for the last quarter / year ending on December 31, 2010, within a period of 60 days from the end of Financial Year i.e. March 01, 2011.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of Corporate Presentation containing latest information regarding business overview, growth strategy, Key Financials etc. of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange that an Extra-Ordinary General Meeting of the members of the Company held on January 10, 2011 and following decisions have been approved by the members of the Company: 1) Amendment in the Articles of Association of the Company for providing power to the Company and its Board of Directors in relation to the issuance of the warrants. 2) To offer, issue and allot 20,00,000 warrants at a price of Rs.400/- per warrant convertible into one equity share of Rs.10/- each fully paid up at price of Rs.400/- per share including premium of Rs.390 p

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of notice of an Extra-ordinary General Meeting of the Company will be held on January 10, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meeting held on December 08, 2010 decided the following: (1) To consider, approve, issue and allot 20,00,000 warrants (each warrant being convertible into one equity share of Rs. 10/-) at a price of Rs. 400/- per warrant, on preferential basis to a person / entities other than Promoter in accordance with provision of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 and its subsequent amendments made from time to time and other applicable rules, regulations and

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 22, 2010, titled "Plethico Pharmaceuticals Ltd - Summary of Financial Performance for 3rd Quarter Ended 30th September 2010".

Plethico Pharmaceuticals Limited has informed the Exchange that "Plethico Pharmaceuticals Limited has received the approval for GMP clearance from the Therapeutic Goods Administration (TGA), Department of Health and Ageing, Australian Government for Company's manufacturing unit situated at Indore-Ahmedabad Road, NH 59 Village Dharavara, Post Kalaria, Indore (M.P.)".

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

IDBI Trusteeship Services Limited has submitted to the Exchange a copy of Disclosure pursuant to Regulation 7(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of the Corporate Presentation Containing latest information regarding business overview, growth strategy, Key Financials etc. of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated August 26, 2010, that "MRI and Prolab to Feature MMA Fighters, Prize Raffles, and Product Samples at Boston UFC Fan Expo, in Partnership with FIGHT! Magazine".

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 05, 2010, titled "Plethico Pharmaceuticals Ltd - Summary of Financial Performance for 2nd Quarter Ended 30th June 2010".

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of the Proceedings of Annual General Meeting held on June 30, 2010.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated June 28, 2010 regarding its Corporate Updates titled "Walmart Stores to Provide Natrol on Shelf with Vitamins in U.S.".

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on June 02, 2010 considered various matters and following decision were taken: (1) The Annual General Meeting of the members of the Company for the accounting year ended on December 31, 2009 has been scheduled to be held on June 30, 2010.(2) That the Register of Members and Share Transfer Books will remain closed from June 28, 2010 to June 30, 2010 (both days Inclusive) for the purpose of distribution of dividend to the members for the accounting year ended on December 31, 2009.

Plethico Pharmaceuticals Limited has informed the Exchange that the Company has received the Certificate of GMP Compliances of a Manufacturer issued by Medicines and Healthcare Products Regulatory Agency(MHRA), U.K. for complying with the principles and guidelines of Good Manufacturing Practice for Capsules- Hard shell, Tablets.

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 13, 2010, titled "Plethico Pharmaceuticals Ltd - Summary of Financial Performance for 1st Quarter Ended 31st March 2010".

Plethico Pharmaceuticals Limited has informed the Exchange that an Extra-Ordinary General Meeting of the members of the Company held on April 19, 2010 following decision have been approved by the members of the Company :- (1) The raise funds to the extent of US$ 100 Million or its Indian rupees equivalent by way of issuance of equity shares and / or FCCB and / or GDR and / or other securities convertible into equity shares and / or such other equity-linked instruments.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of a Corporate Presentation containing latest information regarding business overview, growth strategy, financial analysis etc. of Plethico Pharmaceuticals Limited for the updates of Q4 CY 2009 and YTD December, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_presentaion_16042010.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on March 30, 2010 considered the following: Recommendation of dividend @ 25% i.e. Rs. 2.50 per equity share of the Company involving total outflow of Rs. 851.67 Lacs plus taxes as per applicable rates.

Plethico Pharmaceuticals Limited has informed the Exchange, vide its letter dated March 31, 2010, regarding a press release dated March 30, 2010, with respect to the audited financial results of the Company for quarter and accounting year ended December 31, 2009. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_pr_31032010.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company has, at its meeting held on March 24, 2010 decided the following: (1) To raise up to US$ 100 Million equivalent to Indian rupees from the already Members approved limit US$ 40 Million equivalent to Indian rupees by way of Qualified Institutional Placement (QIP) and /Global Depository Receipts(GDRs) and/or American Depository Receipts (ADRs) and/or Foreign Currency Convertible Bonds (FCCBs) and/or any other security in the domestic / international market(s) subject to statutory approvals as may

Plethico Pharmaceuticals Limited has informed the Exchange that Mr. Amrish Kumar Chourasia has been appointed as the "Company Secretary' and "Compliance Officer" of the Company w.e.f. January 27, 2010 in place of Mr. Ashok Mishra, Company Secretary who has resigned from the Company w.e.f, January 27, 2010.

Plethico Pharmaceuticals Limited has informed the Exchange that "Natrol Inc. USA, a premier marketer, manufacturer, and distributor of nationally branded nutritional products, has been recently certified Organic by Oregon Tilth Certified Organic (OTCO) "Class OP-Organic Processor" for its organic products processed i.e. processing and manufacturing of dietary supplements. Natrol Inc., USA is a wholly owned subsidiary of Plethico Pharmaceuticals Limited".

Plethico Pharmaceuticals Limited had informed the Exchange regarding a Board Meeting scheduled to be on January 29, 2010 to consider, approve and take on record the Un-audited Financial Results for the quarter/year ended on December 31, 2009. The Company has now informed the Exchange that now it has been decided to consider, approve and declare the Audited results instead of Un-audited results for the quarter/year ended on December 31, 2009. As such board meeting proposed on January 29, 2010 has been cancelled and next Board Meeting for considering the quarterly/yearly Audited Financial Result

Plethico Pharmaceuticals Limited has informed the Exchange that " Plethico Pharmaceuticals Limited has been included in the 'Pan American Health Organization' (PAHO) procurement office's list of pre-qualified manufacturer. This is a step to cater our products to the said esteemed organization".

Plethico Pharmaceuticals Limited has informed the Exchange that "Plethico Pharmaceuticals Limited has been accorded the status of "Trading House" for a period of 5 years (upto 31st March 2014) in terms of Foreign Trade Policy 2009-2014. The certification to this effect has been issued by The Directorate General of Foreign Trade, Government of India, Ministry of Commerce & Industry."

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 06, 2009, titled "Natural Products Association Grants Current Good Manufacturing Practices Certification to Natrol". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico06_PR_09112009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2009, titled "Natrol offers Holiday Diet Tips, Carb-Cutting Tricks For Weight Control". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico04_PR_09112009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 05, 2009, titled "Guard Immunity now with new Natrol (R) Immune Boost". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_06112009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated November 04, 2009 regarding a press release dated November 03, 2009, titled "Natrol 5-HTP Wins a 'Best of Supplements' Award in the 'Brain and Wellness' Category". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_04112009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 30, 2009, titled "Plethico Pharmaceuticals Ltd - Summary of Financial Performance for 3rd Quarter ended on September 30, 2009 (unaudited)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PLETHICO_PR_30102009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 28, 2009, titled "Plethico Pharmaceuticals Ltd - Summary of Financial Performance for 2nd Quarter '2009 (unaudited)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PLETHICO_pr_28072009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that the Annual General Meeting of the members of the Company held on June 26, 2009 and following decision have been taken: (1). Company has declared the dividend for the year 2008 of Rs. 2.50 per equity share i.e @ 25%. (2). Dr. G.N. Qazi arid Mr. Pramod Shrivastava are re-appointed as Director of the Company. (3). M/s. N. P. Gandhi & Co. has been appointed as Statutory Auditors of the Company. (4). Authority to Board of Directors u/s 372A of the Companies Act, 1956 for Investment in Tricon Holdings FZE, UAE.

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 07, 2009, titled "Natrol Nutritional Supplements Can Support Immunity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PLETHICO_PR_08052009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 29, 2009, titled "Plethico Pharmaceuticals Ltd - Summary of Financial Performance for 1st Quarter '2009 (unaudited)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PLETHICO_PR_29042009.ZIP target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 31, 2009 for the audited financial results of the Company for quarter and accounting year ended on December 31, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_PR_01042009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on March 31, 2009 considered the proposals and following decision were taken:- (1) The Board has recommended dividend @ 25 % i.e. Rs. 2.50 per equity share of the Company. (2) The Annual General Meeting of the members of the Company for the accounting year ended on December 31, 2008 is scheduled to be held on June 26, 2009. (3) The Register of Members and Share Transfer Books will remain closed from June 22, 2009 to June 26, 2009 (both days inclusive) for the purpose of d

Plethico Pharmaceuticals Limited has informed the Exchange that at the Extra-Ordinary General Meeting of the members of the Company held on March 31, 2009, the following decision have been approved by the members of the Company: (1) The issuance of equity shares and/or FCCB and/or GDR and/or other securities convertible into equity shares and/or such other equity-linked instruments to an extent of US$ 40 Million Indian Rupee equivalent. (2) Authority to Board of Directors to borrow in excess of paid-up capital and free reserve to an extent of Rs. 1200 Crores (Rupees One Thousand Two Hundred Cr

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 09, 2009 decided the following: [1] To borrow, subject to the approval of the Company in general meeting, to the extent of Rs.1200 crores, notwithstanding that the moneys to be borrowed together with the money's already borrowed by the Company (apart from temporary loans, if any, obtained from the Company's bankers in the ordinary course of business) will exceed the aggregate of the paid-up capital of the Company and its free reserves; [2] To consider, subject to t

Plethico Pharmaceuticals Limited has informed the Exchange that: "The manufacturing unit of the Company situated at Kandla Special Economic Zone has been awarded with the "Top Exporter Award" for the year 2007-08 for combined category of manufactured products & services by the Office of Development Commissioner, Kandla Special Economic Zone, Ministry of Commerce and Industry. Plethico Pharmaceuticals Limited has won this award consecutively for the second time. Earlier also Company had won awarded the Top Exporter Award for the year 2003-04."

Plethico Pharmaceuticals Limited has informed the Exchange that Natrol Global FZ LLC, manufacturers of herbal products, shall base their regional headquarters at DuBiotech to cater to the increasing demand for nutritional supplements in the Middle East and Africa regions. Natrol Global is a sister company of Natrol Inc, US, and a subsidiary of Plethico Pharmaceuticals Ltd. a herbal/nutraceutical focus company that engages in the manufacturing, marketing and distribution of pharmaceutical and allied healthcare products. Nutraceuticals are health food supplements that include products such as fu

Plethico Pharmaceuticals Limited has submitted to the Exchange disclosure under regulation 8A(4) of SEBI (SAST) Regulations, 1997. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Plethico_Pledge_11022009.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that: "Plethico Pharmaceuticals Limited has entered into a tie up with Pharma MNC "Molekule (India) Pvt. Ltd., Mumbai" a leading pharmaceutical company having aggressive marketing and distribution network across the country, for marketing some of Natrol's brands in India. The Company is looking to do more tie up's with other Pharma majors in India for promoting it's wellness brands in India".

Plethico Pharmaceuticals Limited has informed the Exchange that the Company will publish the Quarterly / Yearly Audited Financial Results for the last quarter / year ending on December 31, 2008, within a period of 3 months i.e. upto March 31, 2009.